{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:14:04Z","timestamp":1788556444858,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omta.2026.201752","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:36:08Z","timestamp":1778085368000},"page":"201752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of downstream purification process and AAV serotype on protein-impurity clearance"],"prefix":"10.1016","volume":"34","author":[{"given":"Nicolas","family":"B\u00e9ard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9gory","family":"Rouby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Luc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coline","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klo\u00e9","family":"Vanthournout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zin\u00e9dine","family":"Loukili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Santambien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Carapito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0038-6804","authenticated-orcid":false,"given":"Romain","family":"Fragnoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201752_bib1","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: The Rubik\u2019s cube of human gene therapy","volume":"30","author":"Pupo","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201752_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1001263","article-title":"rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis","volume":"13","author":"Shen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201752_bib3","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201752_bib4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omta.2026.201752_bib5","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201752_bib6","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201752_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.2","article-title":"Manufacturing of recombinant adeno-associated viral vectors for clinical trials","volume":"3","author":"Cl\u00e9ment","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201752_bib8","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/JVI.72.3.2224-2232.1998","article-title":"Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus","volume":"72","author":"Xiao","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201752_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/2339702","article-title":"Comprehensive Comparison of AAV Purification Methods: Iodixanol Gradient Centrifugation vs. Immuno-Affinity Chromatography","volume":"2023","author":"Lam","year":"2023","journal-title":"Adv. Cell Gene Ther."},{"key":"10.1016\/j.omta.2026.201752_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2023.464337","article-title":"The downstream bioprocess toolbox for therapeutic viral vectors","volume":"1709","author":"Kilgore","year":"2023","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.omta.2026.201752_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101309","article-title":"Characterization of AAV vectors: A review of analytical techniques and critical quality attributes","volume":"32","author":"Kontogiannis","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201752_bib12","doi-asserted-by":"crossref","first-page":"7965","DOI":"10.1038\/s41467-024-52002-4","article-title":"An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species","volume":"15","author":"Vu Hong","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201752_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101629","article-title":"The amazing AAV capsids: Into the structure-verse","volume":"33","author":"Hsi-Bell","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201752_bib14","article-title":"Shuffling of HVRs in AAV Capsid Reveals a Context-Dependent Role for HVR5 in Peripheral Tissue Detargeting While Ensuring CNS Targeting","author":"Leborgne","year":"2025","journal-title":"Social Science Research Network"},{"key":"10.1016\/j.omta.2026.201752_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-1-59745-210-6_2","article-title":"The Role of the Adeno-Associated Virus Capsid in Gene Transfer","volume":"437","author":"Van Vliet","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omta.2026.201752_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118270","article-title":"A rapid molecular approach for chromosomal phasing","volume":"10","author":"Regan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omta.2026.201752_bib17","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/bit.27808","article-title":"\u201cHigh-risk\u201d host cell proteins (HCPs): A multi-company collaborative view","volume":"118","author":"Jones","year":"2021","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.omta.2026.201752_bib18","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1002\/bit.70029","article-title":"Host Cell Protein Clinical Safety Risk Assessment\u2014An Updated Industry Review","volume":"122","author":"Coye","year":"2025","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.omta.2026.201752_bib19","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/btpr.2640","article-title":"Experience with host cell protein impurities in biopharmaceuticals","volume":"34","author":"Vanderlaan","year":"2018","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.omta.2026.201752_bib20","unstructured":"European Medicines Agency. Guideline on Quality, Non-clinical and Clinical Requirements for Investigational Advanced Therapy Medicinal Products in Clinical Trials. 2019."},{"key":"10.1016\/j.omta.2026.201752_bib21","unstructured":"Guideline on Development, Production, Characterisation and Specification for Monoclonal Antibodies and Related Products. 2016."},{"key":"10.1016\/j.omta.2026.201752_bib22","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/bit.25327","article-title":"Host cell protein testing by ELISAs and the use of orthogonal methods","volume":"111","author":"Zhu-Shimoni","year":"2014","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.omta.2026.201752_bib23","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acs.analchem.7b03965","article-title":"Dual Data-Independent Acquisition Approach Combining Global HCP Profiling and Absolute Quantification of Key Impurities during Bioprocess Development","volume":"90","author":"Husson","year":"2018","journal-title":"Anal. Chem."},{"key":"10.1016\/j.omta.2026.201752_bib24","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jpha.2023.03.009","article-title":"Host cell protein quantification workflow using optimized standards combined with data-independent acquisition mass spectrometry","volume":"13","author":"Hessmann","year":"2023","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.omta.2026.201752_bib25","doi-asserted-by":"crossref","first-page":"9186","DOI":"10.1021\/acs.analchem.5b01377","article-title":"Quantitative Host Cell Protein Analysis Using Two Dimensional Data Independent LC\u2013MSE","volume":"87","author":"Farrell","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1016\/j.omta.2026.201752_bib26","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1021\/acs.analchem.6b04892","article-title":"Host Cell Protein Profiling by Targeted and Untargeted Analysis of Data Independent Acquisition Mass Spectrometry Data with Parallel Reaction Monitoring Verification","volume":"89","author":"Kreimer","year":"2017","journal-title":"Anal. Chem."},{"key":"10.1016\/j.omta.2026.201752_bib27","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/btpr.2397","article-title":"Identification of an IgG CDR sequence contributing to co-purification of the host cell protease cathepsin D","volume":"33","author":"Bee","year":"2017","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.omta.2026.201752_bib28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1167\/iovs.66.6.38","article-title":"Investigating the Immunogenic Potential of Variations in Host Cell Protein Levels in Clinical-Grade AAV8 Products","volume":"66","author":"Seitz","year":"2025","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omta.2026.201752_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101623","article-title":"Characterization of difficult-to-remove host cell proteins in adeno-associated virus downstream processing","volume":"33","author":"Leibiger","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201752_bib30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ejpb.2023.06.019","article-title":"SP3-based host cell protein monitoring in AAV-based gene therapy products using LC-MS\/MS","volume":"189","author":"Smith","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.omta.2026.201752_bib31","article-title":"In-depth host cell protein analysis and viral protein impurity monitoring in adeno-associated virus-based gene therapy products using optimized wide window data-dependent acquisition method","volume":"96","author":"Huo","year":"2024","journal-title":"Anal. Chem."},{"key":"10.1016\/j.omta.2026.201752_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116009","article-title":"A simple and sensitive differential digestion method to analyze adeno-associated virus residual host cell proteins by LC-MS","volume":"242","author":"Hu","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.omta.2026.201752_bib33","doi-asserted-by":"crossref","first-page":"6620","DOI":"10.1128\/JVI.00297-12","article-title":"Human Galectin 3 Binding Protein Interacts with Recombinant Adeno-Associated Virus Type 6","volume":"86","author":"Denard","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201752_bib34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/cr.2016.40","article-title":"Ubiquitin signaling in immune responses","volume":"26","author":"Hu","year":"2016","journal-title":"Cell Res."},{"key":"10.1016\/j.omta.2026.201752_bib35","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1111\/febs.15013","article-title":"Post-translational modifications in capsid proteins of recombinant adeno-associated virus (AAV) 1-rh10 serotypes","volume":"286","author":"Mary","year":"2019","journal-title":"FEBS J."},{"key":"10.1016\/j.omta.2026.201752_bib36","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1128\/jvi.76.5.2043-2053.2002","article-title":"Ubiquitination of both Adeno-Associated Virus Type 2 and 5 Capsid Proteins Affects the Transduction Efficiency of Recombinant Vectors","volume":"76","author":"Yan","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201752_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148296","article-title":"Editorial: Ubiquitin and ubiquitin-like modifications in viral infection and innate immunity","volume":"14","author":"Sparrer","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201752_bib38","first-page":"1","article-title":"Cyclophilin A: A Key Factor in Virus Replication and Potential Target for Anti-Viral Therapy","volume":"21","author":"Dawar","year":"2017","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.omta.2026.201752_bib39","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1128\/JVI.01519-06","article-title":"Cyclophilin A, TRIM5, and Resistance to Human Immunodeficiency Virus Type 1 Infection","volume":"81","author":"Luban","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201752_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01756-19","article-title":"Thioredoxin 2 Negatively Regulates Innate Immunity to RNA Viruses by Disrupting the Assembly of the Virus-Induced Signaling Adaptor Complex","volume":"94","author":"Li","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201752_bib41","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1128\/jvi.64.12.6204-6213.1990","article-title":"Evidence for covalent attachment of the adeno-associated virus (AAV) rep protein to the ends of the AAV genome","volume":"64","author":"Snyder","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201752_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/biot.202300685","article-title":"Molecular design of controllable recombinant adeno-associated virus (AAV) expression systems for enhanced vector production","volume":"19","author":"Johari","year":"2024","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.omta.2026.201752_bib43","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/btpr.50","article-title":"Host cell protein clearance during protein A chromatography: development of an improved column wash step","volume":"24","author":"Shukla","year":"2008","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.omta.2026.201752_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.465586","article-title":"Purification of AAV8 through a scalable two-step monolithic chromatography approach","volume":"1740","author":"Nascimento","year":"2025","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.omta.2026.201752_bib45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/978-1-0716-4087-6_15","article-title":"Chromatographic Purification and Polishing of AAV Particles","volume":"2848","author":"Sedorovitz","year":"2025","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omta.2026.201752_bib46","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/1873-3468.13704","article-title":"Biology of the adenovirus E4orf4 protein: from virus infection to cancer cell death","volume":"594","author":"Kleinberger","year":"2020","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omta.2026.201752_bib47","article-title":"Human adenovirus oncolytic properties and the inhibitory role of E4 orf4 and E4 orf6\/7 on endogenously activated NF-\u03baB","volume":"37","author":"Wang","year":"2024","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.omta.2026.201752_bib48","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/hmg\/ddab300","article-title":"The adeno-associated virus 2 genome and Rep 68\/78 proteins interact with cellular sites of DNA damage","volume":"31","author":"Boftsi","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omta.2026.201752_bib49","doi-asserted-by":"crossref","first-page":"7916","DOI":"10.1128\/JVI.72.10.7916-7925.1998","article-title":"Adeno-associated virus Rep78 protein interacts with protein kinase A and its homolog PRKX and inhibits CREB-dependent transcriptional activation","volume":"72","author":"Di Pasquale","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.omta.2026.201752_bib50","doi-asserted-by":"crossref","first-page":"13634","DOI":"10.1073\/pnas.0504583102","article-title":"How adeno-associated virus Rep78 protein arrests cells completely in S phase","volume":"102","author":"Berthet","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201752_bib51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1743-422X-6-3","article-title":"Production of recombinant AAV vectors encoding insulin-like growth factor I is enhanced by interaction among AAV rep regulatory sequences","volume":"6","author":"Shi","year":"2009","journal-title":"Virol. J."},{"key":"10.1016\/j.omta.2026.201752_bib52","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/sj.gt.3302594","article-title":"Noninvasive monitoring of therapeutic gene transfer in animal models of muscular dystrophies","volume":"13","author":"Bartoli","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201752_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.202300172","article-title":"Advanced mass spectrometry workflows for accurate quantification of trace-level host cell proteins in drug products: Benefits of FAIMS separation and gas-phase fractionation DIA","volume":"23","author":"Beaumal","year":"2023","journal-title":"Proteomics"},{"key":"10.1016\/j.omta.2026.201752_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.202000152","article-title":"An innovative standard for LC-MS-based HCP profiling and accurate quantity assessment: Application to batch consistency in viral vaccine samples","volume":"21","author":"Trauchessec","year":"2021","journal-title":"Proteomics"},{"key":"10.1016\/j.omta.2026.201752_bib55","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1074\/mcp.M500230-MCP200","article-title":"Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition","volume":"5","author":"Silva","year":"2006","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.omta.2026.201752_bib56","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","article-title":"The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences","volume":"50","author":"Perez-Riverol","year":"2022","journal-title":"Nucleic Acids Res."}],"updated-by":[{"DOI":"10.1016\/j.omta.2026.201769","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000}}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X2600087X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X2600087X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:32:24Z","timestamp":1788553944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X2600087X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S3117387X2600087X"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201752","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of downstream purification process and AAV serotype on protein-impurity clearance","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201752"}}